Hall Laurie J Trustee Continues to Hold Position in Edwards Lifesciences Corp (EW)

Hall Laurie J Trustee held its stake in shares of Edwards Lifesciences Corp (NYSE:EW) during the first quarter, Holdings Channel reports. The fund owned 2,105 shares of the medical research company’s stock at the end of the first quarter. Hall Laurie J Trustee’s holdings in Edwards Lifesciences Corp were worth $196,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in EW. Quadrant Capital Group LLC boosted its stake in shares of Edwards Lifesciences Corp by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock valued at $109,000 after buying an additional 41 shares during the last quarter. TCI Wealth Advisors Inc. boosted its stake in shares of Edwards Lifesciences Corp by 30.5% in the third quarter. TCI Wealth Advisors Inc. now owns 1,044 shares of the medical research company’s stock valued at $126,000 after buying an additional 244 shares during the last quarter. Cornerstone Advisors Inc. boosted its stake in shares of Edwards Lifesciences Corp by 28.9% in the third quarter. Cornerstone Advisors Inc. now owns 1,075 shares of the medical research company’s stock valued at $130,000 after buying an additional 241 shares during the last quarter. Advantage Investment Management LLC acquired a new stake in shares of Edwards Lifesciences Corp during the fourth quarter valued at $145,000. Finally, Fuller & Thaler Asset Management Inc. boosted its stake in shares of Edwards Lifesciences Corp by 87.5% in the third quarter. Fuller & Thaler Asset Management Inc. now owns 1,500 shares of the medical research company’s stock valued at $181,000 after buying an additional 700 shares during the last quarter. 83.99% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Edwards Lifesciences Corp (NYSE:EW)

Edwards Lifesciences Corp (NYSE:EW) traded up 0.70% during mid-day trading on Thursday, hitting $94.41. 748,475 shares of the stock were exchanged. Edwards Lifesciences Corp has a 52-week low of $81.12 and a 52-week high of $121.75. The firm has a market cap of $20.06 billion, a price-to-earnings ratio of 36.17 and a beta of 0.53. The company has a 50 day moving average price of $93.58 and a 200 day moving average price of $96.36.

Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings results on Wednesday, February 1st. The medical research company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Edwards Lifesciences Corp had a net margin of 19.22% and a return on equity of 25.00%. The company earned $767.70 million during the quarter, compared to analysts’ expectations of $760.85 million. During the same quarter in the previous year, the business posted $0.64 EPS. The firm’s revenue was up 14.4% on a year-over-year basis. On average, analysts anticipate that Edwards Lifesciences Corp will post $3.41 EPS for the current year.

WARNING: “Hall Laurie J Trustee Continues to Hold Position in Edwards Lifesciences Corp (EW)” was originally published by sleekmoney and is owned by of sleekmoney. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at http://sleekmoney.com/hall-laurie-j-trustee-continues-to-hold-position-in-edwards-lifesciences-corp-ew/1739249.html.

EW has been the subject of a number of analyst reports. Vetr cut shares of Edwards Lifesciences Corp from a “strong-buy” rating to a “buy” rating and set a $106.36 target price for the company. in a research report on Thursday, February 23rd. Northland Securities set a $105.00 target price on shares of Edwards Lifesciences Corp and gave the company a “buy” rating in a research report on Monday, March 20th. Guggenheim raised shares of Edwards Lifesciences Corp from a “neutral” rating to a “buy” rating and set a $120.00 target price for the company in a research report on Tuesday, January 3rd. Canaccord Genuity set a $140.00 target price on shares of Edwards Lifesciences Corp and gave the company a “buy” rating in a research report on Thursday, February 2nd. Finally, Credit Suisse Group AG set a $120.00 target price on shares of Edwards Lifesciences Corp and gave the company a “buy” rating in a research report on Wednesday, February 8th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $118.34.

In other Edwards Lifesciences Corp news, CEO Michael A. Mussallem sold 49,100 shares of the business’s stock in a transaction that occurred on Thursday, February 16th. The shares were sold at an average price of $89.63, for a total transaction of $4,400,833.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 13,720 shares of the business’s stock in a transaction that occurred on Wednesday, April 5th. The stock was sold at an average price of $93.58, for a total transaction of $1,283,917.60. The disclosure for this sale can be found here. Insiders have sold a total of 149,640 shares of company stock valued at $13,939,916 in the last quarter. 2.37% of the stock is currently owned by company insiders.

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

5 Day Chart for NYSE:EW

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/hall-laurie-j-trustee-continues-to-hold-position-in-edwards-lifesciences-corp-ew/1739249.html

Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *